Paul Hudson, via Getty Images (Bloomberg)

Sanofi walks back Paul Hud­son’s promise of ear­ly vac­cine ac­cess for the US, French min­is­ters call it 'u­nac­cept­able'

Sanofi CEO Paul Hud­son’s com­ments yes­ter­day that the US will get first ac­cess to the com­pa­ny’s Covid-19 vac­cine, should it be ap­proved, were met with swift back­lash yes­ter­day in France, both from his own com­pa­ny and a mem­ber of the French gov­ern­ment.

First, hours af­ter Hud­son’s in­ter­view ap­peared on Bloomberg.com, Sanofi emailed jour­nal­ists a terse state­ments walk­ing back its CEO’s re­marks– sort of. The com­pa­ny said that while vac­cines from US pro­duc­tion will be main­ly pre­served for Amer­i­cans, pro­duc­tion ca­pac­i­ty else­where will sup­ply Eu­rope and the rest of the globe. The tech­nol­o­gy Sanofi us­es for its Covid-19 vac­cine can­di­date is pri­mar­i­ly man­u­fac­tured in the US, al­though the com­pa­ny said it is ex­pand­ing ca­pac­i­ty in ex­ist­ing fa­cil­i­ties in Eu­rope and else­where.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.